Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
768.550.62%
QQQ
740.360.95%
BTC/USD
84123.662.4065%
DIA
514.980.58%
GLD
393.001.77%
TLT
80.561.45%

Apnimed Inc

APMDNASDAQ
Trade with Public
Trade with Public
$25.30
-0.21-0.82%
Last update: Sep 22, 6:21 PM
OverviewNewsEarnings ForecastPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Apnimed Analyst Price Targets

Wall Street analyst price targets and consensus rating for Apnimed (APMD).

Price Target Range — 1 Quarters

Analyst Consensus — 4 Analysts

4Buy
Consensus RatingBuy# Analysts4Avg. Consensus PT$50Upside to Avg. PT+98.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 25, 2026LifeSci CapitalFrancois BriseboisInitiateOutperform$50
Aug 25, 2026Cantor FitzgeraldJosh SchimmerInitiateOverweight$60
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
LifeSci Capital Initiates Coverage On Apnimed with Outperform Rating, Announces Price Target of $50

LifeSci Capital analyst Francois Brisebois initiates coverage on Apnimed (NASDAQ:APMD) with a Outperform rating and announces Price Target of $50.
Benzinga Newsdesk

This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Analysts change outlook on top names. See all rating changes, including upgrades/downgrades/initiations. Coverage initiated on various stocks.
Avi Kapoor

PRO
Cantor Fitzgerald Initiates Coverage On Apnimed with Overweight Rating, Announces Price Target of $60

Cantor Fitzgerald analyst Josh Schimmer initiates coverage on Apnimed (NASDAQ:APMD) with a Overweight rating and announces Price Target of $60.
Benzinga Newsdesk

PRO
Evercore ISI Group Initiates Coverage On Apnimed with Outperform Rating

Evercore ISI Group analyst Umer Raffat initiates coverage on Apnimed (NASDAQ:APMD) with a Outperform rating.
Benzinga Newsdesk

PRO
B of A Securities Initiates Coverage On Apnimed with Buy Rating, Announces Price Target of $41

B of A Securities analyst Jason Gerberry initiates coverage on Apnimed (NASDAQ:APMD) with a Buy rating and announces Price Target of $41.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved